HIMS Stock Chart & Stats
$503.10
$20.10(4.02%)
At close: 4:00 PM EDT
$503.10
$20.10(4.02%)
Day’s Range― - ―
52-Week Range$240.00 - $1,200.01
Previous CloseN/A
Volume448.00
Average Volume (3M)1.34K
Market Cap
$109.00B
Enterprise Value$8.74K
Total Cash (Recent Filing)$841.05M
Total Debt (Recent Filing)$1.55B
Price to Earnings (P/E)―
Beta0.09
Next Earnings
Nov 09, 2026EPS Estimate
0.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding224,935,790
10 Day Avg. Volume841
30 Day Avg. Volume1,338
Financial Highlights & Ratios
PEG Ratio-33.04
Price to Book (P/B)13.50
Price to Sales (P/S)3.11
P/FCF Ratio98.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$556.93Price Target Upside10.70% Upside
Rating ConsensusHold
Number of Analyst Covering14
EPS Forecast (FY)-10.01
Revenue Forecast (FY)$54.42B
Bulls Say, Bears Say
Bulls Say
Revenue And Subscriber GrowthRapid revenue growth and a nearly three-million subscriber base indicate broadening demand, stronger platform scale, and greater cross-sell potential. Continued subscriber additions can support recurring revenue and improve operating leverage as Hims & Hers expands conditions, products, and geographies.
Positive Cash GenerationPositive operating and free cash flow despite a reported TTM loss demonstrates that the core model can generate liquidity before accounting profitability fully recovers. This provides funding for product expansion and working capital, although recent quarterly cash usage remains a constraint.
AI Efficiency And EngagementThe AI pilot suggests the platform can increase customer engagement while reducing nonclinical support workload. If these results scale across the subscriber base, lower service costs and faster responses could strengthen retention, capacity, and margins over the next several quarters.
Bears Say
High And Rising LeverageDebt has risen sharply while equity remains comparatively modest, materially reducing financial flexibility. High leverage can increase obligations and constrain investment choices if profitability or cash conversion weakens, making the company more sensitive to execution setbacks during its expansion.
Gross-Margin CompressionSustained margin compression indicates that growth is increasingly coming from lower-margin branded weight-loss and international businesses. Management expects margins to remain below historical levels, which may limit operating leverage and make future earnings growth more dependent on continued scale.
Regulatory And Legal UncertaintyThe FTC complaint creates an ongoing legal overhang with potential costs, while FDA rulemaking affects the timing of certain peptide launches. These issues could require management attention, delay product expansion, and increase uncertainty around the company’s growth and investment plans.
Hims & Hers Health News
HIMS FAQ
What was Hims & Hers Health’s price range in the past 12 months?
Hims & Hers Health lowest stock price was $240.00 and its highest was $1200.01 in the past 12 months.
What is Hims & Hers Health’s market cap?
Hims & Hers Health’s market cap is $109.00B.
When is Hims & Hers Health’s upcoming earnings report date?
Hims & Hers Health’s upcoming earnings report date is Nov 09, 2026 which is in 55 days.
How were Hims & Hers Health’s earnings last quarter?
Hims & Hers Health released its earnings results on Aug 10, 2026. The company reported -$6.288 earnings per share for the quarter, missing the consensus estimate of -$0.85 by -$5.439.
Is Hims & Hers Health overvalued?
According to Wall Street analysts Hims & Hers Health’s price is currently Undervalued.
Does Hims & Hers Health pay dividends?
Hims & Hers Health does not currently pay dividends.
What is Hims & Hers Health’s EPS estimate?
Hims & Hers Health’s EPS estimate is 0.97.
How many shares outstanding does Hims & Hers Health have?
Hims & Hers Health has 224,935,790 shares outstanding.
What happened to Hims & Hers Health’s price movement after its last earnings report?
Hims & Hers Health reported an EPS of -$6.288 in its last earnings report, missing expectations of -$0.85. Following the earnings report the stock price went down -4.037%.
Which hedge fund is a major shareholder of Hims & Hers Health?
Currently, no hedge funds are holding shares in MX:HIMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hims & Hers Health Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$556.93 (10.70% Upside)
$556.93 (10.70% Upside)
Blogger Sentiment
Bullish
MX:HIMS Sentiment 72%
Sector Average 62%
Sector Average 62%
Insider Transactions
Sold Shares
Worth $14.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-46.85%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
93.27%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Hims & Hers Health
Hims & Hers Health, Inc. operates a comprehensive digital health platform that seamlessly links individuals with licensed medical professionals for virtual consultations and ongoing care. Through its user-friendly websites and mobile app, the company delivers a diverse portfolio of health and wellness solutions directly to consumers. This includes access to recurring prescription medications, alongside a wide selection of over-the-counter drugs, devices, cosmetics, and dietary supplements. Its core focus areas are general wellness, sexual health, skincare, and hair care. Specific non-prescription offerings span categories such as: Wellness: encompassing items like vitamin C, melatonin, biotin, and collagen protein supplements. Skincare: including products such as moisturizers, serums, and face washes. Sexual Health: providing essentials like condoms, climax delay sprays and wipes, vibrators, and lubricants. Hair Care: offering specialized shampoos, conditioners, scalp scrubs, and topical treatments like minoxidil. Beyond direct sales, Hims & Hers also distributes health and wellness products via wholesale partnerships. The company's headquarters are located in San Francisco, California.
HIMS Company Deck
HIMS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed a constructive and growth-oriented outlook: strong revenue and subscriber growth, raised guidance, meaningful international scale from the Eucalyptus acquisition, and promising AI-driven engagement and efficiency gains. These positives are tempered by margin compression from mix shift toward branded weight loss and international sales, a GAAP loss driven by one-time costs, short-term negative cash flow in the quarter, and regulatory/legal uncertainties (FTC action and dependence on FDA rulemaking for peptides). Management highlighted liquidity actions and expects AI investments to pay back within 12–18 months, signaling confidence in the path to improved profitability.View all MX:HIMS earnings summariesHIMS Revenue Breakdown
96.60% Online
3.40% Wholesale
HIMS Stock 12 Month Forecast
Average Price Target
$556.93
▲(10.70% Upside)
Technical Analysis
Acadia Healthcare
―
biote
―
Lifestance Health Group
―
EUDA Health Holdings
―
Mobile-health Network Solutions Class A
―